News

26 Jan CDC publication acknowledges Aegis Sciences and Walgreens for their work

The Centers for Disease Control publishes two Morbidity and Mortality Weekly Reports utilizing spike-protein target failure/performance, SGTF/rSGTP, as a proxy to track emerging SARS-CoV-2 variants and vaccine effectiveness against Omicron sublineages related to BA.5 and XBB/XBB.1.5. Acknowledging Aegis Sciences and Walgreens for their work published previously in PLOS1, SGTF/rSTGP monitoring proves to be a critical public health tool for real-time SARS-CoV-2 surveillance.

Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023 | MMWR (cdc.gov)

Spike Gene Target Amplification in a Diagnostic Assay as a Marker for Public Health Monitoring of Emerging SARS-CoV-2 Variants — United States, November 2021–January 2023 | MMWR (cdc.gov)